Edgewood Oncology’s Post

View organization page for Edgewood Oncology, graphic

477 followers

Exciting news from Edgewood Oncology! We have reached a major milestone as the first two patients have been dosed in our Phase 2a trial of BTX-A51, aimed at treating genetically-defined breast cancer. This trial focuses on ER+/HER2- metastatic breast cancer, evaluating the preliminary effectiveness of BTX-A51 in patients with and without GATA3 mutations. This is a significant step forward for those facing limited treatment options and a challenging prognosis. Read the press release and learn more about the proposed role of BTX-A51 in this breast cancer sub-population at www.edgewoodoncology.com #biotech #oncology #breastcancer #precisionmedicine #BTXA51 #edgewoodoncology #clinicaltrials

  • No alternative text description for this image
GEORGIA LI, M.D.

Medical Executive Accomplished In Advancing Clinical Development of SMDs, MABs, SiRNA, CGT to Registration Across Major & Rare Indicators in Organ Fibrosis (NASH, PBC, PSC, IPF, DKD), Neurodegenerative Dz, & IO Oncology

5mo

Zung Thai, congratulations on achieving the key milestone for a novel approach towards target therapy in breast cancer

Like
Reply
Johan E.T. van Hylckama Vlieg

CSO, Innovation Leader, Board Member & Entrepreneur

5mo

Congratulations Zung Thai and team

Like
Reply
Jack Nirenberg

National Account Associate at OncLive | Working With Commercial Oncology Partners on NPP and P2P Marketing Solutions

5mo

Congratulations Zung Thai & Edgewood Oncology!! This is an incredible milestone to reach!

Like
Reply
Rebekah Deane

💥Executive Recruitment💥

5mo

Congratulations to all the team at Edgewood Oncology, such an exciting step!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics